Detalles de la búsqueda
1.
Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.
Mol Carcinog
; 56(3): 1189-1196, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27649287
2.
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.
Int J Cancer
; 138(1): 195-205, 2016 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26152787
3.
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Int J Cancer
; 136(8): 1967-75, 2015 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25242168
4.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Lancet Oncol
; 13(8): 773-81, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22805291
5.
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Clin Cancer Res
; 12(23): 7099-107, 2006 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17145834
6.
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
J Clin Oncol
; 35(3): 352-360, 2017 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27870570
7.
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.
J Clin Oncol
; 31(9): 1231-8, 2013 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23358974
8.
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
J Clin Oncol
; 27(33): 5660-9, 2009 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19858397
Resultados
1 -
8
de 8
1
Próxima >
>>